Novavax COVID-19 vaccine approved for 12 to 17s by MHRA

Nuvaxovid, the COVID-19 vaccine developed by US vaccines specialist Novavax (Nasdaq: NVAX), has today been granted an extension to its existing UK approval, for 12- to 17-year-olds. This extension has been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).

The approval follows a review of the safety, quality and effectiveness of the vaccine in this age group, and expert advice from the government’s independent scientific advisory body, the Commission on Human Medicines.

“Following our review of the safety, quality and effectiveness of Nuvaxovid in 12- to 17-year-olds, I am pleased to confirm that that the vaccine has now been authorised in this age group. In reaching this decision, we have taken advice from the government’s independent scientific advisory body, the Commission on Human Medicines, “ said MHRA chief executive Dr June Raine.